James B Lewin - Biogen Inc | 人才画像

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Comparative Efficacy of Diroximel Fumarate, Ozanimod and Interferon Beta-1A for Relapsing Multiple Sclerosis Using Matching-Adjusted Indirect Comparisons

Tammy Jiang, Mathura Shanmugasundaram,Ivan Bozin,Mark S. Freedman,James B. Lewin,Changyu Shen,Tjalf Ziemssen,Douglas L. Arnold

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCHno. 10 (2024)

引用0浏览0WOS引用

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate

Mark Gudesblatt,Barbara Bumstead,Marijean Buhse,Myassar Zarif,Sarah A. Morrow,Jacqueline A. Nicholas,Laura M. Hancock,Jeffrey Wilken,Joanna Weller, Nicole Scott,Anne Gocke,James B. Lewin,Olivia Kaczmarek,Jason P. Mendoza,Daniel Golan

ADVANCES IN THERAPYno. 8 (2024): 3059-3075

引用0浏览0WOS引用

Change in Disease Modifying Therapy from DMF to DRF in People with Multiple Sclerosis and the Impact on CD4/CD8 T Cells (P8-6.016)

Fatema Rahaman, Matthew Jo,Joanna Weller,Olivia Kaczmarek,Kaitlyn Jaenicke,Steven Baek,Marijean Buhse,Barbara Bumstead,Myassar Zarif,Jason Mendoza,Jennifer Smrtka, Nicole Scott,James Lewin,Mark Gudesblatt

Neurology（2024）

引用0浏览0引用

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Barry A. Singer,Sibyl Wray,Mark Gudesblatt,Barbara Bumstead,Tjalf Ziemssen, Ashley Bonnell,Matthew Scaramozza,Seth Levin, Mathura Shanmugasundaram,Hailu Chen,Jason P. Mendoza,James B. Lewin,Sai L. Shankar

Neurology and Therapypp.1-13, (2024)

引用0浏览0WOS引用

Evaluating the Effect of Dimethyl Fumarate on Subclinical Biomarkers in a Real-World Patient Cohort

Stephen Krieger,Myassar Zarif,Barbara Bumstead,Marijean Buhse,Olivia Kaczmarek,Jared Srinivasan,Nuno Barros,Diana Sima,Annemie Ribbens,Wim Van Hecke,James B. Lewin,Jason P. Mendoza,Mark Gudesblatt

Journal of neuroimmunologypp.578397-578397, (2024)

引用0浏览0WOS引用

Diroximel Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: NEDA-3 after Re-Baselining in the Phase 3 EVOLVE-MS-1 Study

James D. Bowen,Jessica Stulc,Samuel F. Hunter,Hailu Chen,James B. Lewin,Matthew Scaramozza,Ivan Bozin,Florian Then Bergh

Advances in Therapy (2024)

引用0浏览0WOS引用

Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005)

Sophia Woodson,Edward Gettings,Chu-Yueh Guo,Sylvia Klineova, Jong-Mi Lee,Rebecca Romero,Aljoeson Walker, Kinyee Fong,Jason Mendoza,Nicholas Belviso, Boyang Bian,James Lewin,Sai Shankar

Neurology（2024）

引用0浏览0引用

Safety, Tolerability, and Efficacy of Diroximel Fumarate in a Cohort of Black Patients with Multiple Sclerosis from the Phase 3 EVOLVE-MS-1 Study

Samuel F. Hunter,John W. Lindsey,Benjamin Osborne, Bethany Schreiber,Filipe Branco,Seth Levin,James B. Lewin,Matthew Scaramozza, Zhe Tian,Ariel Antezana

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2024)

引用0浏览0WOS引用

Patterns of Disease-Modifying Therapy Utilization Before, During, and after Pregnancy and Postpartum Relapses in Women with Multiple Sclerosis

Riley Bove,Angela Applebee, Katrina Bawden, Celeste Fine,Anna Shah,Robin L. Avila,Nicholas Belviso,Filipe Branco, Kinyee Fong,James B. Lewin, Jieruo Liu,Sarah M. England,Megan Vignos

Multiple sclerosis and related disorderspp.105738-105738, (2024)

引用0浏览0WOS引用

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies

Lilyana Amezcua,Yang Mao-Draayer,Wendy S. Vargas,Rebecca Farber, Sara Schaefer,Filipe Branco,Sarah M. England,Nicholas Belviso,James B. Lewin,Jason P. Mendoza,Sai L. Shankar

Neurology and Therapyno. 3 (2023): 883-897

引用1浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn